Connect public, paid and private patent data with Google Patents Public Datasets

Gaba b1a receptor disruptions, compositions and methods relating thereto

Info

Publication number
WO2003001883A3
WO2003001883A3 PCT/US2002/020270 US0220270W WO2003001883A3 WO 2003001883 A3 WO2003001883 A3 WO 2003001883A3 US 0220270 W US0220270 W US 0220270W WO 2003001883 A3 WO2003001883 A3 WO 2003001883A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
gaba
invention
methods
present
provides
Prior art date
Application number
PCT/US2002/020270
Other languages
French (fr)
Other versions
WO2003001883A2 (en )
Inventor
Robert G Wisotzkey
Original Assignee
Deltagen Inc
Robert G Wisotzkey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The present invention relates to compositions and methods relating to the characterization, function, and uses of GABA-B1A. Specifically, the present invention provides transgenic animals comprising disruptions in GABA-B1A receptors. The present invention also provides methods of identifying agents that modulate GABA-B1A, useful models, and potential for various disease states and disease conditions.
PCT/US2002/020270 2001-06-26 2002-06-25 Gaba b1a receptor disruptions, compositions and methods relating thereto WO2003001883A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US30110201 true 2001-06-26 2001-06-26
US60/301,102 2001-06-26

Publications (2)

Publication Number Publication Date
WO2003001883A2 true WO2003001883A2 (en) 2003-01-09
WO2003001883A3 true true WO2003001883A3 (en) 2004-01-22

Family

ID=23161949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/020270 WO2003001883A3 (en) 2001-06-26 2002-06-25 Gaba b1a receptor disruptions, compositions and methods relating thereto

Country Status (2)

Country Link
US (1) US20030056238A1 (en)
WO (1) WO2003001883A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US7561919B2 (en) * 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US7120489B2 (en) 2000-05-08 2006-10-10 Brainsgate, Ltd. Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the BBB and cerebral blood flow
US7117033B2 (en) * 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
WO2003090599A3 (en) * 2002-04-25 2004-11-25 Brainsgate Ltd Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7636597B2 (en) * 2002-11-14 2009-12-22 Brainsgate, Ltd. Surgical tools and techniques for stimulation
US20090299418A1 (en) * 2004-08-23 2009-12-03 Brainsgate Ltd. Concurrent bilateral spg modulation
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIRST ET AL.: "Molecular and pharmacological characterisation of the GABAB1 knockout mouse", SOC. NEUROSCI., vol. 27, no. 2, 2001, pages 1854, XP002968371 *
MARTIN AND OLSEN: "GABA in the Nervous System", 2000, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, PA, article OLSEN ET AL.: "Function of GABAA receptors: insights from mutant and kncockout mice", pages: 81 - 96, XP002968370 *
PANGALOS ET AL.: "Epileptogenesis and pre-pulse inhibition in GABAB1 deficient mice", SOCIETY NEUROSCI., vol. 27, no. 2, 2001, pages 1855, XP002968372 *
PROSSER ET AL.: "Epileptogenesis and enhanced prepulse inhibition in GABA-B1-deficient mice", MOL. CELLUAR NEUROSCI., vol. 17, June 2001 (2001-06-01), pages 1059 - 1070, XP002968373 *
SANGER ET AL.: "GABA(B) receptor function in the ileum and urinary bladder of wildtype and GABA)B1) subunit in null mice", AUTON. AUTACOID PHARMACOL., vol. 22, no. 3, June 2002 (2002-06-01), pages 147 - 154, XP002968374 *
SULLIVAN ET AL.: "Coexpression of full-length gamma-aminobutyric acid-B (GABA-B) receptors with truncated receptors with truncated receptors and metabotropic glutamate receptor 4 supports the GANA-B heterodimer as the functional receptor 1", J. PHARMACOL. AND EXP. THERAPEUTICS, vol. 293, no. 2, 2000, pages 460 - 467, XP002968375 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation

Also Published As

Publication number Publication date Type
WO2003001883A2 (en) 2003-01-09 application
US20030056238A1 (en) 2003-03-20 application

Similar Documents

Publication Publication Date Title
WO2001056990A3 (en) Pyridine derivates as potentiators of glutamate receptors
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2007043433A1 (en) Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient and therapeutic method for liver disease
WO2008036273A3 (en) Receptor family profiling
WO2007023841A1 (en) Hair growth agent composition
WO2005120400A3 (en) Methods and apparatuses for bone restoration
WO2003020295A1 (en) Remedies or preventives for allergic diseases comprising processed peanut seed coat
WO2000031258A3 (en) Human orphan g protein-coupled receptors
WO2004090145A3 (en) Compounds and methods to enhance raav transduction
CN300882683S (en) Carabiner (2)
WO2003066802A3 (en) Gene expression analysis using nicking agents
WO2006044449A3 (en) Cgrp receptor antagonists
CN300901798S (en) Crystal ashtray (6)
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
Murray Opera dramatics.
WO2006044504A8 (en) Cgrp receptor antagonists
RU2007130151A (en) Neanilinovye derivatives isothiazol-3 (2H) -on-1, 1-dioxides as modulators of the liver X receptors
WO2006047196A3 (en) Cgrp receptor antagonists
Amsha The Term “Theatre” between Egypt and Levant
O'Rourke The End of Globalization: Lessons from the Great Depression
WO2006041830A3 (en) Cgrp receptor antagonists
GB0226342D0 (en) Animal faeces remover (scoop)
CN300864766S (en) Adapter (3)
WO2007038407A3 (en) Compositions and methods for treating nervous system disorders
CN300873794S (en) Tripod head (2)

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP